Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 15/20 | 0.73 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4299277 | 0.85 | DGAT1 (0.73) | DGAT1GLAL3MBTL1NPC1RAB9A | |
| SCHEMBL4291530 | 0.85 | DGAT1 (1.00) | DGAT1GLAL3MBTL1NPC1RAB9A | |
| SCHEMBL4291949 | 0.84 | DGAT1 (0.71) | DGAT1NPC1RAB9A | |
| SCHEMBL4294211 | 0.84 | DGAT1 (0.71) | DGAT1NPC1RAB9A | |
| SCHEMBL4296854 | 0.84 | DGAT1 (0.98) | DGAT1GLAL3MBTL1NPC1RAB9A | |
| SCHEMBL4297548 | 0.83 | DGAT1 (0.67) | DGAT1L3MBTL1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL4296723 | 0.82 | DGAT1 (0.65) | DGAT1L3MBTL1SMN1; SMN2 | |
| SCHEMBL4296522 | 0.81 | DGAT1 (0.80) | DGAT1GLAL3MBTL1NPC1RAB9A | |
| SCHEMBL4407196 | 0.81 | DGAT1 (0.66) | DGAT1GLAL3MBTL1NPC1RAB9A | |
| SCHEMBL4296708 | 0.80 | DGAT1 (1.00) | DGAT1SMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286791-A1 | Amide Compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286791-A1 | Amide Compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286791-A1 | Amide Compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286791-A1 | Amide Compounds | DLAT, DGAT2, DGAT1 | DGAT1 3/4885GLA 321/4885L3MBTL1 1367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.